IDEAYA Biosciences(IDYA)

SOUTH SAN FRANCISCO, CABiotechnology2 H-1B visas (FY2023)

Focus: IDEAYA Biosciences is a public oncology-focused biotech developing personalized synthetic medicines using precision medicine approaches. The company operates at mid-cap scale (501-1,000 employees) with a pure-play R&D model centered on targeted cancer therapies.

Oncology

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

501-1000

Open Jobs

20-1 this month

Stable — net -1 jobs in 30d

17 added, 18 removed. Backfill posture.

Should You Work at IDEAYA Biosciences?

AI assessment

High-risk, high-reward opportunity best suited for scientists/clinical professionals comfortable with preclinical/early clinical emphasis and biotech volatility.

Why Work Here

Pure oncology focus with 10 active pipeline programs spanning Phase 1-3, including Phase 3 lead Darovasertib in uveal melanoma with clear near-term catalysts

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$23M

Pipeline & Clinical Trials

IDE892

NSCLC Adenocarcinoma

PHASE_1

Clinical Trials (1)

NCT07277413A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1

Help build intelligence for IDEAYA Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Heavy investment in R&D (554% intensity, $130M spend in FY2025) signals deep commitment to drug discovery and translational science roles

Public company status with $157M cash provides stability and equity upside potential for early-career biotech professionals seeking growth equity

Watch Out For

Severe financial burn: $113M net loss in FY2025 with declining revenue ($23M vs. $51M YoY) and only 8 months of cash runway at current burn rate
Early-stage pipeline (5 Phase 1 programs) means high clinical failure risk and extended path to meaningful revenue milestones or profitability

Generated by Claude from IDEAYA Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

IDE397

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT04794699Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase 1

IDE849

Small-cell Lung Cancer

PHASE_1_2

Clinical Trials (1)

NCT07174583A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2

GSK4418959

Neoplasms, Colorectal

PHASE_1_2

Clinical Trials (1)

NCT06710847A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Phase 1/2

IDE196

Metastatic Uveal Melanoma

PHASE_1_2

Clinical Trials (1)

NCT03947385Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2

Darovasertib

Uveal Melanoma

PHASE_2

Clinical Trials (1)

NCT05907954(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Phase 2

IDE196

Metastatic Uveal Melanoma

PHASE_2_3

Clinical Trials (1)

NCT05987332IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3

Darovasertib

Uveal Melanoma

PHASE_3

Clinical Trials (1)

NCT07015190Neoadjuvant Darovasertib in Primary Uveal Melanoma

Phase 3

IDE034

Esophageal Squamous Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Phase 1

IDE574

ER+, HER 2- Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT07540572A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Phase 1/2

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Oncology

H-1B (2023): 2 approvals

Publications: 23 in PubMed

SEC Filings: 2 available

Open Roles: 20 active jobs

Therapeutic Area Focus

Oncology

10 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$23M54%

R&D Spend

$130M(554%)45%

Net Income

-$113M

Hiring Trend

Actively Hiring

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

May 2018

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

I Wish I Had Known That! Impactful Guidance and Perspectives for a Fulfilling Career in Toxicology.

International journal of toxicology

2025

PMID:39951653

Author Correction: A multilineage screen identifies actionable synthetic lethal interactions in human cancers.

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

IDEAYA Biosciences(IDYA)

Should You Work at IDEAYA Biosciences?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · IDEAYA Biosciences(10)

Open Jobs (20)

Principal Research Scientist, Analytical Chemistry

Associate Director, Quality Management System

Director, Regional Marketing Lead (West Region)

Director, Regional Marketing Lead (East Region)

Senior Director, Medical Writing

Director, Commercial Accounting

Senior Director, Clinical Science

Senior Director, Trade, Channel, & Distribution

Senior Regional Business Director (Northeast)

Senior Regional Business Director (West Region)

Senior Regional Business Director (Southeast)

Senior Regional Business Director (Central Region)

Senior Medical Director, Patient Safety & Pharmacovigilance

Director, ADC & MSAT

Senior Clinical Data Manager

Director, Clinical Science

Senior Patent Agent

Senior Principal Research Scientist, Computational Chemistry

Senior Director, Health Economics and Outcomes Research / Real World Evidence

Director, Intellectual Property

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Private Funding (SEC Form D)

Research Publications(10)